ad6548b723
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics.md - Domain: health - Claims: 0, Entities: 4 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
28 lines
No EOL
1.6 KiB
Markdown
28 lines
No EOL
1.6 KiB
Markdown
# Diamond Therapeutics
|
|
|
|
**Location:** Toronto, Canada
|
|
|
|
**Focus:** Psilocybin-assisted therapy for anxiety disorders
|
|
|
|
**Stage:** Phase 2a clinical trials
|
|
|
|
## Clinical Programs
|
|
|
|
**Generalized Anxiety Disorder (GAD):**
|
|
- Phase 2a psilocybin trial data being contributed to ARPA-H EVIDENT initiative
|
|
- GAD represents largest single anxiety disorder population (~40M US sufferers)
|
|
- Larger addressable market than treatment-resistant depression (TRD) or PTSD
|
|
|
|
## Strategic Position
|
|
|
|
Diamond Therapeutics is notable as a Canadian company selected for US government-funded research infrastructure (ARPA-H EVIDENT), demonstrating international data integration into US regulatory pathways. The GAD indication differentiates from most psychedelic research focused on depression or PTSD.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-24** — Selected as ARPA-H EVIDENT research team, contributing Phase 2a psilocybin GAD trial data
|
|
|
|
## Analysis
|
|
|
|
The GAD indication is strategically significant: if psilocybin demonstrates efficacy for generalized anxiety disorder, the addressable population exceeds TRD and PTSD combined. GAD affects ~6.8M US adults annually (3.1% of population), with lifetime prevalence near 9%. Current first-line treatments (SSRIs, SNRIs, benzodiazepines) have limited efficacy and significant side effect profiles, creating unmet medical need.
|
|
|
|
Diamond's inclusion in ARPA-H EVIDENT despite being a non-US company indicates that psychedelic research infrastructure is genuinely international, with US regulatory agencies willing to incorporate foreign clinical data into domestic approval pathways. |